These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 25223380)

  • 1. Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions.
    Witkiewicz AK; Knudsen ES
    Breast Cancer Res; 2014 May; 16(3):207. PubMed ID: 25223380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer.
    Witkiewicz AK; Cox DW; Rivadeneira D; Ertel AE; Fortina P; Schwartz GF; Knudsen ES
    Oncogene; 2014 Jul; 33(30):3980-91. PubMed ID: 24121271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis.
    Liu X; Gu X; Sun L; Flowers AB; Rademaker AW; Zhou Y; Kiyokawa H
    BMC Cancer; 2014 Feb; 14():57. PubMed ID: 24485087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer.
    Citron F; Segatto I; Vinciguerra GLR; Musco L; Russo F; Mungo G; D'Andrea S; Mattevi MC; Perin T; Schiappacassi M; Massarut S; Marchini C; Amici A; Vecchione A; Baldassarre G; Belletti B
    Cancer Res; 2020 Mar; 80(5):1064-1077. PubMed ID: 31862778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.
    McClendon AK; Dean JL; Rivadeneira DB; Yu JE; Reed CA; Gao E; Farber JL; Force T; Koch WJ; Knudsen ES
    Cell Cycle; 2012 Jul; 11(14):2747-55. PubMed ID: 22751436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models.
    Kumarasamy V; Nambiar R; Wang J; Rosenheck H; Witkiewicz AK; Knudsen ES
    Oncogene; 2022 Jul; 41(27):3524-3538. PubMed ID: 35676324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer.
    Dai M; Zhang C; Ali A; Hong X; Tian J; Lo C; Fils-Aimé N; Burgos SA; Ali S; Lebrun JJ
    Sci Rep; 2016 Oct; 6():35383. PubMed ID: 27759034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
    Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
    Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Methylation and expression of gene p16INK4a and RB in breast carcinoma].
    Zhao YF; Shen SP; Jiang JY; Geng H; Guo JG; Xie LP
    Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):377-81. PubMed ID: 21055153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.
    Witkiewicz AK; Rivadeneira DB; Ertel A; Kline J; Hyslop T; Schwartz GF; Fortina P; Knudsen ES
    Am J Pathol; 2011 Sep; 179(3):1171-8. PubMed ID: 21756866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
    Finn RS; Dering J; Conklin D; Kalous O; Cohen DJ; Desai AJ; Ginther C; Atefi M; Chen I; Fowst C; Los G; Slamon DJ
    Breast Cancer Res; 2009; 11(5):R77. PubMed ID: 19874578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.
    Dean JL; McClendon AK; Hickey TE; Butler LM; Tilley WD; Witkiewicz AK; Knudsen ES
    Cell Cycle; 2012 Jul; 11(14):2756-61. PubMed ID: 22767154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.
    Harada M; Morikawa M; Ozawa T; Kobayashi M; Tamura Y; Takahashi K; Tanabe M; Tada K; Seto Y; Miyazono K; Koinuma D
    Cancer Sci; 2019 Jan; 110(1):209-220. PubMed ID: 30343527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
    Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
    Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
    Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.